Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial

The global prevalence of ulcerative colitis is increasing, and induction and maintenance of remission is a crucial therapeutic goal. We assessed the efficacy and safety of filgotinib, a once-daily, oral Janus kinase 1 preferential inhibitor, for treatment of ulcerative colitis. This phase 2b/3, doub...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Lancet (British edition) 2021-06, Vol.397 (10292), p.2372-2384
Hauptverfasser:	Feagan, Brian G, Danese, Silvio, Loftus, Edward V, Vermeire, Séverine, Schreiber, Stefan, Ritter, Timothy, Fogel, Ronald, Mehta, Rajiv, Nijhawan, Sandeep, Kempiński, Radosław, Filip, Rafał, Hospodarskyy, Ihor, Seidler, Ursula, Seibold, Frank, Beales, Ian L P, Kim, Hyo Jong, McNally, John, Yun, Chohee, Zhao, Sally, Liu, Xiaopeng, Hsueh, Chia-Hsiang, Tasset, Chantal, Besuyen, Robin, Watanabe, Mamoru, Sandborn, William J, Rogler, Gerhard, Hibi, Toshifumi, Peyrin-Biroulet, Laurent
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Adverse events Analysis Antagonists Arthritis Care and treatment Clinical trials Colitis, Ulcerative Colitis, Ulcerative - drug therapy Corticoids Corticosteroids Crohn's disease Dosage Dose-Response Relationship, Drug Double-Blind Method Double-blind studies Endoscopy Enzyme inhibitors Female Humans Immunosuppressive agents Inflammatory bowel disease Intolerance Janus kinase Janus Kinase Inhibitors Kinases Life Sciences Maintenance Male Monoclonal antibodies Pathogenesis Patients Pharmacokinetics Placebos Pyridines Pyridines - administration & dosage Remission Remission Induction Safety Treatment Outcome Triazoles Triazoles - administration & dosage Tumor necrosis factor Tumor necrosis factor-TNF Tumors Ulcerative colitis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!